Trellus Health PLC (GB:TRLS)
LSE:TRLS
Top Page
Trellus Health PLC
(LSE:TRLS)
Select Model
Select Model
Rating:51Neutral
Price Target:
0.75 p
â–²(88.50% Upside)
Action:ReiteratedDate:01/23/26
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
Trellus Health PLC (TRLS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£547.27K
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)3.88
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees31
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding273,637,600
10 Day Avg. Volume590,654
30 Day Avg. Volume1,032,652
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.09
Price to Sales (P/S)9.31
P/FCF Ratio-0.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trellus Health PLC Business Overview & Revenue Model
Company Description
Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers TrellusElevate, a proprietary HIPAA-compliant technology platform to coordinate and deliver personalized care remotely th...
How the Company Makes Money
null...
Trellus Health PLC Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0.00 |
| Gross Profit | 359.00K | 114.00K | 19.00K | 18.00K | 25.00K | 0.00 |
| EBITDA | -6.93M | -7.16M | -6.50M | -8.27M | -5.87M | -1.52M |
| Net Income | -6.89M | -7.78M | -6.34M | -8.81M | -5.90M | -1.52M |
Balance Sheet | ||||||
| Total Assets | 9.22M | 12.14M | 20.29M | 25.91M | 36.80M | 4.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.57M | 4.34M | 12.17M | 19.09M | 31.98M | 3.68M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 513.00K | 371.00K | 786.00K | 822.00K | 1.52M | 122.00K |
| Stockholders Equity | 8.71M | 11.77M | 19.50M | 25.09M | 35.27M | 4.25M |
Cash Flow | ||||||
| Free Cash Flow | -6.16M | -7.86M | -7.63M | -11.53M | -8.49M | -1.32M |
| Operating Cash Flow | -6.16M | -7.32M | -5.27M | -8.62M | -4.77M | -1.30M |
| Investing Cash Flow | -291.00K | -540.00K | -2.35M | -2.91M | -3.72M | -1.35M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 38.52M | 10.02M |
Trellus Health PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | £42.07M | 2.68 | 10.00% | ― | ― | ― | |
52 Neutral | £18.16M | -3.33 | -58.72% | ― | -30.77% | -6.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £547.27K | -0.12 | -56.95% | ― | ― | ― | |
51 Neutral | £6.83M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
45 Neutral | £20.09M | -2.69 | -58.27% | ― | 37.39% | -126.19% | |
39 Underperform | £8.52M | ― | 425.97% | ― | -4.48% | 61.09% |
* Healthcare Sector Average
GB:TRLS
Trellus Health PLC
0.20
-1.65
-89.19%
GB:COG
Cambridge Cognition Holdings
39.00
5.00
14.71%
GB:IXI
IXICO plc
7.38
-0.50
-6.41%
GB:RENX
Renalytix
1.95
-6.05
-75.63%
GB:KOO
Kooth
116.00
-13.00
-10.08%
GB:ABDX
Abingdon Health PLC
8.00
1.50
23.08%
Trellus Health PLC Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Issues New Shares on Loan Note Conversion
Neutral
Mar 10, 2026
Trellus Health plc has issued 16,438,845 new ordinary shares following the conversion of £50,000 in principal under the second tranche of its secured convertible loan notes. The issuance was slightly scaled back to offset previously over-allo...
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Issues New Shares on Loan Note Conversion, Updates Voting Rights
Neutral
Mar 10, 2026
Trellus Health plc has issued 16,438,845 new ordinary shares following the conversion of £50,000 of principal from the second tranche of its secured convertible loan notes, with the issuance slightly reduced to offset an earlier over-allotmen...
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Issues New Shares on Loan Note Conversion, Updates Voting Rights
Neutral
Mar 2, 2026
Trellus Health has issued 16,454,134 new ordinary shares following the conversion of £50,000 of principal under the second tranche of its secured convertible loan notes. The new shares are expected to be admitted to trading on AIM around 5 Ma...
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Completes Loan Note Conversion and Increases Share Capital
Neutral
Feb 23, 2026
Trellus Health has converted approximately £65,000 of principal and accrued interest from its secured convertible loan notes into 16,804,593 new ordinary shares, completing the conversion of its first tranche notes. The new shares are expecte...
Business Operations and StrategyPrivate Placements and Financing
Trellus Health Wins J&J Contract Extension as TrialSet Deployments Scale Up
Positive
Feb 18, 2026
Trellus Health has secured a six-month extension to its contract with Johnson Johnson Health Care Systems to mid-2026, maintaining existing economic terms to provide its Trellus Elevate platform to IBD patients prescribed JJ therapies. The extens...
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Issues New Shares on Conversion of Loan Notes
Neutral
Feb 18, 2026
Trellus Health plc has issued 5,637,205 new ordinary shares following the conversion of £21,000 of principal under its secured convertible loan notes, in line with shareholder approvals granted in January. The new shares are expected to be ad...
Private Placements and FinancingRegulatory Filings and Compliance
Trellus Health Issues New Shares on Loan Note Conversion
Neutral
Feb 11, 2026
Trellus Health has issued 5,538,461 new ordinary shares following the conversion of £27,000 of principal under its secured convertible loan notes, a move that modestly expands its equity base. The new shares are expected to be admitted to tra...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Trellus Health Deepens Pharma and CRO Ties as TrialSetâ„¢ Deployment Gathers Pace
Positive
Feb 3, 2026
Trellus Health reported ongoing operational progress across its key verticals, particularly in clinical trials, where it signed 12‑month contracts with global CROs ICON and PSI to deploy its Trellus TrialSet™ solution in Takeda- and Sa...
Private Placements and FinancingShareholder Meetings
Trellus Health Issues New Shares to Settle Loan Note Fees
Neutral
Jan 29, 2026
Trellus Health plc has issued 19,230,769 new ordinary shares in lieu of cash payment for settlement fees related to its secured convertible loan notes, following shareholder approval at a recent general meeting. The new shares are expected to be a...
Business Operations and StrategyShareholder Meetings
Trellus Health Wins Overwhelming Shareholder Backing at General Meeting
Positive
Jan 20, 2026
Trellus Health plc announced that all resolutions put to shareholders at its General Meeting on 20 January 2026 were duly passed on a poll, with each motion receiving more than 99.8% of votes cast in favour. The strong shareholder support provides...
Business Operations and StrategyExecutive/Board Changes
Trellus Health Grants Share Options to Chairman to Align Incentives with Shareholders
Positive
Jan 19, 2026
Trellus Health has granted options over 807,541 ordinary shares to its chairman, Kevin Murphy, under the company’s existing share option plan at an exercise price of 0.525p, matching the pricing of a recent loan note arrangement with Mount S...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Trellus Health Seeks Up to £5m via Convertible Loan Notes to Extend Cash Runway
Negative
Dec 30, 2025
Trellus Health plans to raise up to £5 million via a 12‑month secured convertible loan note facility from an institutional investor, with warrants attached and funds available in staged tranches, subject to shareholder approval at a gen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.